Akèy › Kansè san › Distrik Columbia › Washington
Etid klinik pou Kansè san nan Washington, DC
19 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- MedStar Georgetown University Hospital, Washington D.C.
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi lwen
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Ap rekriteFaz 1/2Volontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi lwen
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Ap rekriteFaz 1/2Volontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Longitudinal Studies of Patient With FPDMM
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 1/2Volontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Ap rekriteEtid obsèvasyon
- The Center for Cancer and Blood Disorders, Bethesda · 7 mi lwen
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Ap rekriteFaz 1
- Childrens National Medical Center, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Ap rekrite
- Georgetown University School of Medicine, Washington D.C.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Children's National Medical Center, Washington D.C.
- Nih/Niaid, Bethesda · 7 mi lwen
- Nih/Nhlbi, Bethesda · 7 mi lwen
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi lwen
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Ap rekriteFaz 1/2Volontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Ap rekriteEtid obsèvasyon
- George Washington University, Washington D.C.
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's National Medical Center, Washington D.C.
- National Cancer Institute, Pediatric Oncology Branch, Bethesda · 7 mi lwen
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- New York City, NY26 etid
- Boston, MA25 etid
- Seattle, WA18 etid
- Baltimore, MD18 etid
- Los Angeles, CA17 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Nashville, TN13 etid
- Columbus, OH13 etid
- Edison, NJ13 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Kansè ovè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.